← All indications
Carcinoma, Intraductal, Noninfiltrating
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Subtype terms (1)
More specific conditions that are subtypes of Carcinoma, Intraductal, Noninfiltrating in the MeSH hierarchy.
Drugs by status
Approved for this indication (1)
Phase 4 trials (3)
Phase 2 trials (22)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (14)
- National Cancer Institute (NCI)
- Academic and Community Cancer Research United
- Kaohsiung Medical University
- Kyoto University
- NRG Oncology
- North Central Cancer Treatment Group
- Southwest Oncology Group
- NSABP Foundation
- National Taiwan University
- Sun Yat-Sen University
- City of Hope National Medical Center
- American College of Surgeons
- Government of Taiwan
- Mackay Medical College
Organization Involved with Phase 2 Indications (29)
- Incyte
- AstraZeneca
- Pfizer
- Atossa Genetics, Inc.
- Windy Hill Medical, Inc.
- United States Army
- University of Pittsburgh
- Baylor University
- University of London
- Harvard University
- Duke University
- George Mason University
- Georgetown University
- Johns Hopkins University
- New York University
- Northwestern University
- Ohio State University
- Sichuan University
- University of Miami
- University of Southern California
- Mayo Clinic
- University of California, San Francisco
- Vanderbilt University
- Department of Defense
- University of Minnesota
- University of Texas at Houston
- University of Wisconsin
- Inova Health System
- Besins Healthcare
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (9)